ACCEL PIOGLITAZONE 30 MG — DIN 02303450
PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) : 30 MG · ACCEL PHARMA INC · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is ACCEL PIOGLITAZONE?
ACCEL PIOGLITAZONE 30 MG contains PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) : 30 MG. It is listed in the Health Canada Drug Product Database under DIN 02303450, held by ACCEL PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 20-Mar-2020. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is ACCEL PIOGLITAZONE used for?
Monotherapy or in combination with sulfonylurea or metformin to decrease blood glucose levels in patients with type 2 diabetes mellitus (NIDDM).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Pioglitazone cost around the world?
Pioglitazone is listed on 11 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 3 | 55 | USD███.██ |
| Czechia | max producer price (ex-factory) | 8 | 33 | CZK███.██ |
| Australia | ex-manufacturer | 3 | 18 | AUD███.██ |
| Saudi Arabia | public | 18 | 18 | SAR███.██ |
| Italy | prezzo al pubblico (classe A) | 6 | 15 | EUR███.██ |
| South Africa | single exit price | 9 | 10 | ZAR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 7 | 7 | EUR███.██ |
| Greece | producer price (ex-factory) | 7 | 7 | EUR███.██ |
| Luxembourg | reimbursement | 4 | 4 | EUR███.██ |
| Bahrain | retail (max) | 2 | 3 | BHD███.██ |
| United Kingdom | hospital | 3 | 3 | GBP███.██ |
173 pack listings across 70 brand entries and 11 price bases, refreshed 08 Sep 2026. Ranges span every Pioglitazone pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Pioglitazone in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
23 holders have a Canadian DIN containing Pioglitazone, across 77 DINs, of which 12 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| TEVA CANADA LIMITED | 6 | 3 | ACT PIOGLITAZONE, TEVA-PIOGLITAZONE | Sourceable in Canada |
| ACCORD HEALTHCARE INC | 3 | 3 | ACH-PIOGLITAZONE | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 3 | 3 | JAMP PIOGLITAZONE | Sourceable in Canada |
| MINT PHARMACEUTICALS INC | 3 | 3 | MINT-PIOGLITAZONE | Sourceable in Canada |
| ACCEL PHARMA INC | 6 | 0 | ACCEL PIOGLITAZONE, PIOGLITAZONE | No marketed DIN |
| RANBAXY PHARMACEUTICALS CANADA INC. | 6 | 0 | RAN-PIOGLITAZONE | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 3 | 0 | MYLAN-PIOGLITAZONE | No marketed DIN |
| PHARMASCIENCE INC | 3 | 0 | PMS-PIOGLITAZONE | No marketed DIN |
| PHARMEL INC | 3 | 0 | PHL-PIOGLITAZONE | No marketed DIN |
| PRO DOC LIMITEE | 3 | 0 | PRO-PIOGLITAZONE | No marketed DIN |
| RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED | 3 | 0 | RATIO-PIOGLITAZONE | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 3 | 0 | SANDOZ PIOGLITAZONE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 30 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Not explicitly detailed in the provided text (mentions 15, 30, 45 mg tablets). |
| Storage | Not explicitly detailed in the provided text (section header exists but content not in snippet). |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Pioglitazone |
|---|---|
| ATC code | A10BG03 |
| AHFS class | 68:20.28 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02303450 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2303450 |
| Brand name | ACCEL PIOGLITAZONE |
| Generic / active ingredient | PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) : 30 MG |
| Market authorization holder | ACCEL PHARMA INC |
| Health Canada schedule | Prescription |
| ATC code | A10BG03 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A10BG |
| Current status | CANCELLED POST MARKET |
| Status date | 20-Mar-2020 |
| Original market date | 2009-06-02 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Indicated as monotherapy or in combination with sulfonylurea or metformin. Dosage should be titrated based on HbA1c response. Re-evaluate if excessive weight gain occurs.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
NYHA Class I-IV heart failure; hypersensitivity; serious hepatic impairment; pregnancy; active or history of bladder cancer; uninvestigated macroscopic haematuria.
Warnings and precautions
Can cause fluid retention leading to congestive heart failure. Increased risk of bladder cancer and bone fractures (especially in females). Potential for hepatic injury.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
12 of 77 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-PIOGLITAZONE | 30 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | 02339587 |
| ACH-PIOGLITAZONE | 45 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | 02339595 |
| ACH-PIOGLITAZONE | 15 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | 02391600 |
| ACT PIOGLITAZONE | 45 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 02302896 |
| ACT PIOGLITAZONE | 30 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 02302888 |
| ACT PIOGLITAZONE | 15 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 02302861 |
| JAMP PIOGLITAZONE | 15 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02397307 |
| JAMP PIOGLITAZONE | 45 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02365537 |
| JAMP PIOGLITAZONE | 30 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02365529 |
| MINT-PIOGLITAZONE | 15 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | 02326477 |
2 · Same class — other molecules in ATC A10BG
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Pioglitazone | ACCEL PIOGLITAZONE · ACH-PIOGLITAZONE · ACT PIOGLITAZONE · ACTOS · +20 more | 77 | 12 | Yes |
| Rosiglitazone | AVANDIA · DOM-ROSIGLITAZONE · MYLAN-ROSIGLITAZONE · PHL-ROSIGLITAZONE · +3 more | 21 | 3 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A10B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A10BD | Combinations Of Oral Blood Glucose Lowering Drugs · Glimepiride And Rosiglitazone · Linagliptin And Empagliflozin · Metformin And Alogliptin · Metformin And Canagliflozin · +8 more | 123 | 67 |
| A10BH | Alogliptin · Linagliptin · Saxagliptin · Sitagliptin | 91 | 63 |
| A10BA | Metformin | 122 | 45 |
| A10BK | Canagliflozin · Dapagliflozin · Empagliflozin · Ertugliflozin | 42 | 30 |
| A10BX | Nateglinide · Repaglinide · Tirzepatide | 54 | 30 |
| A10BB | Acetohexamide · Chlorpropamide · Glibenclamide · Gliclazide · Glimepiride · +1 more | 112 | 23 |
| A10BJ | Albiglutide · Dulaglutide · Exenatide · Liraglutide · Lixisenatide · +1 more | 34 | 13 |
| A10BF | Acarbose | 6 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ACCEL PIOGLITAZONE called?
The same molecule, Pioglitazone, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| NOVAPIO | Latin | Czechia |
| Actos | Latin | Australia, Czechia, South Africa |
| ARX-PIOGLITAZONE | Latin | Australia |
| PIOGLITAZONE ACCORD | Latin | Czechia |
| Vexazone | Latin | Australia |
| PIOGLITAZON ACTAVIS | Latin | Czechia |
| PIOGLITAZON VIATRIS | Latin | Czechia |
| DUETACT | Latin | Bahrain |
| PIOGLITAZON MYLAN | Latin | Czechia |
| ACTOSMET | Latin | Bahrain |
| COMPETACT | Latin | Czechia |
| Glitamomet | Latin | Saudi Arabia |
| NOVAPIO PLUS | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.